Literature DB >> 32665179

Efficacy of Ultrasound-Guided Transversus Thoracic Muscle Plane Block on Postoperative Opioid Consumption After Cardiac Surgery: A Prospective, Randomized, Double-Blind Study.

Muhammed Enes Aydin1, Ali Ahiskalioglu2, Irem Ates3, Ibrahim Hakki Tor4, Ferhat Borulu5, Ozlem Dilara Erguney3, Mine Celik1, Nazim Dogan3.   

Abstract

OBJECTIVES: The postoperative analgesic efficacy of transversus thoracic muscle plane block (TTMPB) has not yet been evaluated sufficiently. This randomized controlled study evaluated the effect of TTMPB on postoperative opioid consumption in patients undergoing cardiac surgery.
DESIGN: Prospective, randomized, double-blind study. SETTINGS: Single institution, academic university hospital. PARTICIPANTS: Forty-eight adult patients having cardiac surgery with median sternotomy.
INTERVENTIONS: Patients were randomly assigned to receive preoperative ultrasound-guided TTMPB with either 20 mL of 0.25% bupivacaine or saline bilaterally. Postoperative analgesia was administered intravenously in the 2 groups 4 times a day with 1000 mg of paracetamol and patient-controlled analgesia with fentanyl.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was opioid consumption in the first 24 hours. Secondary outcomes included postoperative pain scores, first analgesic requirement time, rescue analgesia, intensive care discharge time, and side effects. Compared with the control group (median 465 µg, interquartile range 415-585), the transversus thoracic muscle plane (TTMP) group (median 255 µg, interquartile range 235-305) had reduced postoperative 24-hour opioid consumption (p < 0.001). Pain scores were significantly lower in the TTMP group compared with the control group up to 12 hours after surgery both at rest and active movement (p < 0.001). Compared with the TTMP group, the proportion of postoperative nausea and pruritus was statistically higher in the control group (p < 0.001).
CONCLUSIONS: A single preoperative TTMPB provided effective analgesia and decreased opioid requirements in patients undergoing cardiac surgery.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Transversus thoracic muscle plane block; cardiac surgery; postoperative analgesia; poststernotomy pain

Year:  2020        PMID: 32665179     DOI: 10.1053/j.jvca.2020.06.044

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

Review 1.  Chest Wall Nerve Blocks for Cardiothoracic, Breast Surgery, and Rib-Related Pain.

Authors:  Richa Sharma; Aaron Louie; Carolyn P Thai; Anis Dizdarevic
Journal:  Curr Pain Headache Rep       Date:  2022-01-28

2.  Single-centre, double-blind, randomised, parallel-group, superiority study to evaluate the effectiveness of general anaesthesia and ultrasound-guided transversus thoracis muscle plane block combination in adult cardiac surgery for reducing the surgical stress response: clinical trial protocol.

Authors:  A A Gde Putra Semara Jaya; Aida Rosita Tantri; Aldy Heriwardito; Arif Mansjoer
Journal:  BMJ Open       Date:  2021-11-11       Impact factor: 2.692

3.  Efficacy and Safety of Ultrasound Guided-Deep Serratus Anterior Plane Blockade With Different Doses of Dexmedetomidine for Women Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial.

Authors:  Xia Xu; Xingfang Chen; Wenchao Zhu; Jing Zhao; Yanchao Liu; Caiping Duan; Yingying Qi
Journal:  Front Med (Lausanne)       Date:  2022-02-07

4.  The Analgesic Efficacy of Ultrasound-Guided Bilateral Transversus Thoracic Muscle Plane Block After Open-Heart Surgeries: A Randomized Controlled Study.

Authors:  Mohamed Ahmed Hamed; Maged Labib Boules; Mina Mahrous Sobhy; Mahdy Ahmed Abdelhady
Journal:  J Pain Res       Date:  2022-03-05       Impact factor: 3.133

Review 5.  Ultrasound-Guided Regional Anesthesia-Current Strategies for Enhanced Recovery after Cardiac Surgery.

Authors:  Cosmin Balan; Serban-Ion Bubenek-Turconi; Dana Rodica Tomescu; Liana Valeanu
Journal:  Medicina (Kaunas)       Date:  2021-03-25       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.